There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research ...

We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a ...

Arvinas, Inc. (ARVN) has been beaten down lately with too much selling pressure. While the stock has lost 54.9% over the past ...

Charles Schwab Investment Management Inc. lifted its stake in shares of Arvinas, Inc. (NASDAQ:ARVN – Free Report) by 1.0% during the 4th quarter, according to its most recent disclosure with the ...

Arvinas’ cash burn and lack of pipeline candidates hurt its outlook. See why ARVN stock is a sell, despite a healthy cash ...

Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of Arvinas in a report issued on Tuesday, March 18th. Cantor Fitzgerald analyst L. Watsek now forecasts that the ...

Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

Wells Fargo analyst Derek Archila lowered the firm’s price target on Arvinas (ARVN) to $26 from $60 and keeps an Overweight rating on the ...

The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...

Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...